May 13, 2024 – Page 8 – Goldea Capital

Schouw & Co. share buy-back programme, week 19 2024

Written by Customer Service on May 13, 2024. Posted in Public Companies.

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Trading day No. of shares Average price Amount Accumulated until 3/5/2024 85,700 528.19 45,265,502 Monday, 6 May 2024 1,400 558.58 782,012 Tuesday, 7 May 2024 1,400 562.43 787,402 Wednesday, 8 May 2024 1,300 569.08 739,804 Thursday, 9 May 2024...

Intapp to Participate in Upcoming Investor Conference

Written by Customer Service on May 13, 2024. Posted in Public Companies.

PALO ALTO, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Intapp (NASDAQ: INTA), a leading global provider of AI-powered solutions for professionals at advisory, capital markets, and legal firms, today announced that senior management will attend and present at the following upcoming investor conference: J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference Date: Tuesday, May 21, 2024Location: Boston, Massachusetts Presentation: 9:30am ET A live webcast of the event and archived webcast will be accessible from the “News and Events” section of the company’s investor relations website at https://investors.intapp.com/. About Intapp Intapp software helps professionals unlock their teams’ knowledge, relationships, and operational insights to increase value for their firms. Using the power...

Stride Autism Centers Opens New Facility in Sioux Falls to Extend Autism Support in South Dakota

Written by Customer Service on May 13, 2024. Posted in Mergers And Acquisitions.

Stride Center Sioux Falls, South Dakota Stride Autism Centers Opens New Facility in Sioux Falls to Extend Autism Support in South Dakota SIOUX FALLS, S.D., May 13, 2024 (GLOBE NEWSWIRE) — Stride Autism Centers (“Stride”), a mission-driven provider of evidence-based therapy for children with autism, proudly announces the opening of its new center in Sioux Falls, South Dakota. This expansion is a significant step in Stride’s mission to increase access to specialized autism services throughout the Midwest. Located at 5000 E 57th St, Sioux Falls, SD, the new facility offers Stride’s renowned full-day Applied Behavior Analysis, or ABA therapy programs. Known for their expertise in early childhood intervention, Stride maintains a 1:1 therapist-to-child ratio, ensuring personalized treatment plans for preschool-aged...

Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®) Ended first quarter 2024 with $84.0 million of cash and cash equivalents and no debt SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer Key developments from Q1 2024 and the year to date include: Presented data from 40mg pharmacokinetic run-in cohort of ongoing EVANGELINE study at the AACR annual meeting...

Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vision and Vision-Associated Structures by ANX007 in Geographic Atrophy (GA) Presented at ARVO 2024; Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in GA Expected in mid-2024 Clinical Proof of Concept (POC) Data for ANX1502, an Oral Classical Pathway Inhibitor for Chronic Autoimmune Conditions, on Track for Second Half of 2024 Robust Balance Sheet with Cash, Cash Equivalents, and Short-term Investments of Approximately $264.9 Million as of March 31, 2024, and Anticipated Runway into mid-2026 BRISBANE, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Annexon, Inc....

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

OXFORD, United Kingdom, May 13, 2024 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. “So far in 2024 we have continued to make strides across our programs. Notably, we received clearance from the FDA on an IND to progress VTP-1000 in a first in human clinical trial in celiac disease, as well as clearance from the Australian Ethics Committee on this trial. We expect to begin our Phase 1 trial of VTP-1000 in participants with celiac disease in the coming months. Additionally, we reported topline final data...

Nano Dimension Announces Q1/2024 Conference Call to Discuss Quarterly Results

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Participants Are Welcome to Listen June 3rd at 9:00 am ET Waltham, Mass., May 13, 2024 (GLOBE NEWSWIRE) — Nano Dimension Ltd. (Nasdaq: NNDM, “Nano Dimension” or the “Company”), a leading supplier of Additively Manufactured Electronics (“AME”) and multi-dimensional polymer, metal & ceramic Additive Manufacturing (“AM”) 3D printers, announced today that it will release its financial results for the first quarter of 2024 before the Nasdaq market opens on Monday, June 3rd, 2024. Mr. Yoav Stern, Chief Executive Officer and Member of the Board of Directors, Mr. Tomer Pinchas, Chief Financial Officer & Chief Operating Officer, and Mr. Julien Lederman, VP of Corporate Development, of Nano Dimension will host a conference call on June 3rd, 2024, at 9:00 a.m. ET, to discuss the financial results. Participants can register for...

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025. Completed enrollment of patients in COMPANION-003, a Phase 2 study of CTX-009 in patients with advanced colorectal cancer (CRC); top-line data from Stage 1 are expected by mid-year 2024. Enrollment in the Phase 1b combination study of CTX-471 (CD137 agonist antibody) and KEYTRUDA® in patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC)...

XBP Europe Holdings, Inc. Reports First Quarter 2024 Results

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

First Quarter Highlights ● Revenue of $40.4 million, down 5.7% year-over-year (7.3% on a constant currency basis)● Gross margin grew to 24.6%, a 270 bps increase sequentially and 250 bps increase year-over-year● Net loss of $2.2 million includes $0.8 million of FX losses ● High margin Technology segment grew to 28.4% of revenues, a 120 bps increase sequentially and 690 bps increase year-over-year● Awarded a multi-year contract with His Majesty’s Passport Office (“HMPO”) for a nationwide project in the UK with a Total Contract Value (“TCV”) of approximately $40 million LONDON and SANTA MONICA, Calif., May 13, 2024 (GLOBE NEWSWIRE) — XBP Europe Holdings, Inc. (“XBP Europe” or the “Company”) (NASDAQ: XBP), a pan-European integrator of bills, payments, and related solutions and services seeking to enable the digital transformation...

Erdene Announces Q1 2024 Results and Provides Bayan Khundii Gold Project Update

Written by Customer Service on May 13, 2024. Posted in Earnings Releases And Operating Results.

HALIFAX, Nova Scotia, May 13, 2024 (GLOBE NEWSWIRE) — Erdene Resource Development Corp. (TSX:ERD; MSE:ERDN) (“Erdene” or the “Company”) is pleased to announce operating and financial results for the three months ended March 31, 2024, and to provide an update on progress at its Bayan Khundii Gold Project (“BK” or “Project”), being developed with Mongolian Mining Corporation (“MMC”). This release should be read in conjunction with the Company’s Q1-2024 Condensed Consolidated Interim Financial Statements and MD&A, available on the Company’s website and SEDAR+. Peter Akerley, Erdene’s President and CEO stated, “During the first quarter, Erdene and MMC closed their Strategic Alliance and formally launched construction of the Bayan Khundii Gold Project, one of the highest grade, open pit gold mines under...

Day: May 13, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice